Literature DB >> 15969939

Design and evaluation of compound metformin/glipizide elementary osmotic pump tablets.

Defang Ouyang1, Shufang Nie, Wei Li, Hong Guo, Hui Liu, Weisan Pan.   

Abstract

A simple elementary osmotic pump (EOP) system that could deliver metformin hydrochloride (MT) and glipizide (GZ) simultaneously for extended periods of time was developed in order to reduce the problems associated with multidrug therapy of type 2 non-insulin-dependent diabetes mellitus. In general, both highly and poorly water-soluble drugs are not good candidates for elementary osmotic delivery. However, MT is a highly soluble drug with a high dose (500 mg) while GZ is a water-insoluble drug with a low dose (5 mg) so it is a great challenge to pharmacists to provide satisfactory extended release of MT and GZ. In this paper sodium carbonate was used to modulate the solubility of GZ within the core and MT was not only one of the active ingredients but also the osmotic agent. The optimal EOP was found to deliver both drugs at a rate of approximately zero order for up to 10 h in pH 6.8, independent of environment media. In-vivo evaluation was performed relative to the equivalent dose of conventional MT tablet and GZ tablet by a cross-study in six Beagle dogs. The EOP had a good sustained effect in comparison with the conventional product. The prototype design of the system could be applied to other combinations of drugs used for cardiovascular diseases, diabetes, etc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15969939     DOI: 10.1211/0022357056370

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  2 in total

1.  Development and evaluation of controlled porosity osmotic pump for nifedipine and metoprolol combination.

Authors:  Rajagopal Kumaravelrajan; Nallaperumal Narayanan; Venkatesan Suba
Journal:  Lipids Health Dis       Date:  2011-04-11       Impact factor: 3.876

2.  Osmotic drug delivery system as a part of modified release dosage form.

Authors:  Rajesh A Keraliya; Chirag Patel; Pranav Patel; Vipul Keraliya; Tejal G Soni; Rajnikant C Patel; M M Patel
Journal:  ISRN Pharm       Date:  2012-07-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.